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Background: MicroRNAs (miRNAs) are a class of small RNAs that regulate gene
expression. They are aberrantly expressed in many human cancers and are potential
therapeutic targets and molecular biomarkers.
Methods: In this study, we for the first time validated the reported data on the entire
set of published differential miRNAs (102 in total) through a series of transcriptome-wide
experiments. We have conducted genome-wide miRNA profiling in 17 urothelial carcinoma
bladder tissues and in nine normal urothelial mucosa samples using three methods: (1)
An Illumina HT-12 microarray hybridization (MA) analysis (2) a suppression-subtractive
hybridization (SSH) assay followed by deep sequencing (DS) and (3) DS alone.
Results: We show that DS data correlate with previously published information in 87%
of cases, whereas MA and SSH data have far smaller correlations with the published
information (6 and 9% of cases, respectively). qRT-PCR tests confirmed reliability of the
DS data.
Conclusions: Based on our data, MA and SSH data appear to be inadequate for studying
differential miRNA expression in the bladder.
Impact: We report the first comprehensive validated database of miRNA markers of
human bladder cancer.
Keywords: microRNA, bladder cancer, molecular markers, intracellular regulatory pathways, transcriptome
analysis
INTRODUCTION
Bladder cancer (BC) is one of the most common cancers in indus-
trially developed countries. Approximately 386,300 new BC cases
and 150,200 deaths caused by BC were registered worldwide in
2008 (Jemal et al., 2008). The risk of developing BC is associ-
ated with smoking and with exposure to several other carcinogens
(Kiriluk et al., 2012).
Genetic factors such as chromosomal aberrations (Hoglund,
2012), specific single nucleotide polymorphisms (SNPs) (Golka
et al., 2011), mutations (Castillo-Martin et al., 2010), and epi-
genetic peculiarities (Kim and Kim, 2012) may contribute to
tumorigenesis and the progression of BC. Some molecular fea-
tures may serve as diagnostic and/or prognostic markers of tumor
growth, invasiveness and metastatic potential as well as signs of
disease progression (Castillo-Martin et al., 2010). Molecular diag-
nostics based on the detection of biomarkers in tissues or in
biological fluids may be the key to detecting BC early.
At present, the most commonly used molecular markers for
BC diagnostics are protein-coding genes and their products which
show differential expression in tumor samples compared to nor-
mal bladder tissue (Knowles, 2008). However, non-coding small
RNA molecules may be useful alternative BC biomarkers. Small
non-coding RNAs take part in the regulation of major biological
processes such as cell division, apoptosis, differentiation, growth,
migration, etc. (Eddy, 2001; Zabolotneva et al., 2010). The best-
studied non-coding RNAs are microRNAs (miRNAs). MiRNAs
are 21—25-nucleotide-long RNA molecules that regulate post-
transcriptional gene expression (Boyd, 2008). MiRNAs join the
RNA-induced silencing complex in order to regulate a targeted
messenger RNA (mRNA) through the repression of its transla-
tion and/or by guiding enzymatic cleavage of the mRNA itself
(Hannon, 2002).
More than half of miRNA genes are located in cancer-
associated genomic regions or in fragile chromosomal sites (Calin
et al., 2004). A variety of aberrantly expressed miRNAs are also
associated with different cancers (Calin et al., 2004).MiRNAsmay
act as oncogenes or tumor suppressors. Furthermore, different
cancer types, stages, and differentiation grades may have unique
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miRNA expression signatures; this makes miRNAs promising
biomarkers for cancer diagnosis and the prediction of tumor
progression.
Expression profiles of miRNAs in cancerous and normal cells
may shed light on the mechanisms of bladder carcinogenesis
and can be helpful in developing BC diagnostic and prognostic
assays. Previously, a comprehensive database of miRNAs asso-
ciated with BC was created by performing a systematic search
for published literature that reported the isolation and charac-
terization of expression of BC-specific miRNAs (http://bladder.
pparser.net/MIRMarkers.php) (Zabolotneva et al., 2012).
Overall, we identified 95 miRNAs that were differentially
expressed in BC tissues and seven miRNAs that were differen-
tially methylated in BC vs. non-cancer patients. We summarized
this information in a publically available database (http://bladder.
pparser.net/MIRMarkers.php) which includes miRNA names,
their roles in BC, and the supporting primary literature.
However, the information about the potential diagnostic util-
ity of these biomarkers was largely missing. Here, we evaluate
a complete pool of published miRNA BC markers according
to universal criteria in a series of single assays using three
experimental approaches. We used Illumina HT-12 microarray
hybridization (MH), suppression subtractive hybridization (SSH)
followed by deep sequencing (DS), and DS alone to detect dif-
ferential expression of miRNAs in BC tissues vs. normal bladder
tissues. We investigated 17 human bladder urothelial carcinoma
tissues and nine normal urothelial mucosa samples. The results
of DS experiments were significantly closer to the literature as
compared to the results of the SSH and MH assays. DS anal-
yses allowed us to trace the expression of 38/102 individual
marker miRNAs; the SSH and MH methods provided data for
42 and 33 marker miRNAs, respectively. According to our DS
results, we were able to estimate, for the first time, sensitivity
scores (Pencina et al., 2008) of the entire pool of bladder-marker
miRNAs.
MATERIALS AND METHODS
TISSUE COLLECTION AND RNA ISOLATION
Tissue samples from malignant tumors were obtained from
patients operated on for BC at P.A. Hertzen Moscow Clinical
Oncology Institute (Moscow, Russia) from 2009 to 2011. Normal
bladder mucosae came from an autopsy of undiseased cases.
Tissue samples from non-cancer controls were gathered at the
same time from the Pathology Department of the Faculty of
Medicine at the Moscow State University. Each sample was evalu-
ated by a pathologist to confirm the diagnosis. All tumor samples
used in this study contained >80% of tumor cells. Tissue sam-
ples were immediately placed in RNAlater (Qiagen, Germany)
and then stored at −80◦C. In total, 23 samples from tumors
and 26 samples from normal bladder tissues were analyzed. The
mean age of cancer patients at the time of resection was 62
years (range 44–82). The information on age, disease stage, and
grade of the individual patients is shown on Supplementary Table
S1. The mean age of healthy tissue donors was 42 years with a
median of 45 (range 20–71). Frozen tissue was homogenized in
Trizol (Invitrogen, USA). RNA was isolated following the man-
ufacturer’s protocol. Purified RNA was dissolved in RNase-free
water and stored at −80◦C. The study was approved by local
ethical committees at D. Rogachyov Federal Research Center of
Pediatric Hematology, Oncology and Immunology, Moscow State
University, P.A. Herzen Moscow Oncological Research Institute
and Shemyakin-Ovchinnikov Institute of Bioorganic chemistry.
cDNA LIBRARY GENERATION FOR SSH
Two mixed RNA samples were prepared for SSH analysis. Sample
1 contained total RNA extracted from nine BC tissues. Sample
2 contained total RNA extracted from three normal bladder tis-
sues in equal quantities. Amplified double-stranded cDNA was
prepared from sample 1 and sample 2 RNAs using the Switching
Mechanism at the 5′ end of the RNA Transcript (SMART) (Zhu
et al., 2001). Subtractive hybridization was performed using the
SSH method in both directions (sample 1 vs. sample 2 and vice
versa) by Evrogen (Moscow, Russia) as described in (Diatchenko
et al., 1996). The supplement contains a description of SSH and
all oligonucleotide sequences (Supplementary Table S2).
For SSH libraries, we conducted one lane of 60-bp paired-end
read sequencing using an Illumina GAIIx sequencer, thus gen-
erating ∼45 million sets of paired end reads. Sequencing was
conducted at Genoanalytica (Moscow, Russia).
GENE EXPRESSION MICROARRAY EXPERIMENTS
A total of 26 tissue samples, including 17 cancer and nine normal
bladder mucosa specimens, were selected for microarray anal-
ysis. Total RNA was extracted using TRIzol (Life Technologies,
USA) and then reverse-transcribed to cDNA and cRNA using
the Ambion TotalPrep cRNA Amplification Kit (Invitrogen,
USA). cRNA was quantified using a NanoDrop ND-1000
Spectrophotometer (NanoDrop Technologies, USA) and adjusted
to a concentration of 150 ng/mL. Seven hundred and fifty
nanogram of each library was hybridized onto the bead arrays
using Illumina HumanHT-12v4 Expression BeadChip (Illumina,
USA). It has >25,000 annotated human genes and >48,000
probes derived from the NCBI RefSeq (Build 36.2, Rel 22)
and UniGene (Build 199) databases. The (MH) experiments
were done at the University of Lethbridge, at the laboratory of
Olga Kovalchuk. Full microarray datasets are available upon the
request to the authors.
SEQUENCING DATA ANALYSIS
The sequenced SSH libraries contained 25,517 and 33,329 dif-
ferent assembled contigs for cancer and normal tissue with a
total of 102 MM and 54 MM reads, respectively. Further anal-
ysis was carried out with PostParser software (http://postparser.
net) developed at the Shemyakin-Ovchinnikov Institute that
allows mapping and annotating sequences of interest. For a map-
ping algorithm, we used the BLAST-like alignment tool (BLAT)
(http://genome.ucsc.edu) with further manual fine-tuning. To
distinguish target sequences, we annotated out the dataset from
the National Center for Biotechnology Information (NCBI)
Expressed Sequence Tags database (http://www.ncbi.nlm.nih.
gov/dbEST), with intron-exon boundary information provided
by the NCBI Reference Sequences project (http://www.ncbi.nlm.
nih.gov/RefSeq). The database of mapped and annotated contigs
is available online at (http://bladder.pparser.net.)
Frontiers in Genetics | Cancer Genetics November 2013 | Volume 4 | Article 247 | 2
Zabolotneva et al. MicroRNA markers of human bladder cancer
SMALL RNA ANALYSIS
We analyzed eight cancer tissue specimens and two mixed normal
tissue specimens, each of which included two or three normal tis-
sue samples. Small RNAs from total RNA extracts were cloned
as previously described (Brennecke et al., 2007; Aravin et al.,
2008). Following PCR amplification, the libraries were sequenced
on an Illumina GAIIx platform. The number of reads varied
between the libraries, the mean value was 5.04 million reads per
library. The sequencing was done in the California Institute of
Technology, laboratory of Alexei Aravin. Small RNA sequencing
datasets are available upon the request to the authors.
BIOINFORMATIC ANALYSIS OF SMALL RNA LIBRARIES
Illumina adapters were trimmed from the 3′-end of raw reads, and
reads shorter than 16nt were discarded. The remaining sequences
were collapsed into a non-redundant list and mapped to the ref-
erence human genome using Bowtie (version 1.1.2) (Langmead
et al., 2009). Up to two mismatches were allowed. The sequences
that failed to map to the genome were mapped against the arti-
ficially introduced sequences. The multiplicity count of mapped
sequences was normalized to the total number of reads that
mapped to the genome. All further bioinformatic analyses were
done using PostParser.
qRT-PCR ASSAY
We used TaqMan probe-based qRT-PCR assay to assess micro
RNA transcription for the same RNA samples as were used for
micro RNA libraries construction and sequencing. Megaplex RT
Primers, Human Pool B v. 3.0 (Applied Biosystems) were used
to amplify micro RNAs, and specific TaqMan probe assays hsa-
miR-100, 143, 183, 199A, 200A, 203, 205 (Life Technologies) were
used tomeasure expression of miR100, 143, 183, 199A, 200A, 203,
and 205, respectively. Each experiment was performed at least in
quadruplicate.
RESULTS
EXPERIMENTAL VALIDATION OF miRNA MARKERS WITH SSH
The SSH method for transcriptome analysis is based on the selec-
tive PCR amplification of differential cDNAs (Diatchenko et al.,
1996). We employed the SSH to enrich differential transcripts
when comparing the two pooled RNA samples corresponding to
BC and normal bladder tissues. The BC-pooled sample contained
a mixture of nine BC RNA samples, while the normal sample had
six pooled normal bladder RNAs. We obtained cDNA-converted
subtracted libraries that were enriched for either cancer-specific
(BC+) or normal-tissue-specific (BC−) cDNAs. Following DS
(∼21 million sets of paired-end reads for BC+ and ∼23 mil-
lion sets of paired-end reads for BC-libraries on the Illumina
GAIIx platform), we obtained a normalized digital gene expres-
sion profile for 42/102 (41%) BC miRNA markers identified in
the literature. The status of miRNA (up- or down-regulation
in BC) corresponded to the published biomarker data in only
four entries (9.5% of the cases) (Figure 1B). However, for two
miRNAs (miR141 andmiR205), contradictory data were reported
[up-regulation in Billerey et al. (2001); Aravin et al. (2008); down-
regulation in Adachi et al. (2011)]. According to our SSH data,
miR141, miR21, and miR29C are down-regulated, and miR205 is
FIGURE 1 | Congruence of experimental data from three different
assays according to miRNA expression in bladder cancer (MA MH,
microarray hybridization analysis; SEQ DS, high-throughput deep
sequencing analysis; SSH, suppressive subtractive hybridization
analysis; PD, published data analysis). (A) Comparison of published data,
microarray hybridization and DS data. (B) Comparison of published data,
SSH and DS data. (C) Comparison of published data, SSH and microarray
hybridization data. (D) Comparison of DS, SSH, and microarray hybridization
data.
up-regulated (online Dataset 1, http://small.mrna.ru/files/). miR-
NAs were considered to be differentially expressed if they met
the following criteria: (1) the total normalized number of reads
in both BC and normal libraries is greater or equals to 10, and
(2) the average BC and normal bladder signals differ at least
1.5-times. The cancer-to-normal ratio was calculated for all dif-
ferential BC signals according to the formula SRBC/SRN, where
SRBC and SRN are normalized numbers of reads for the BC and
for normal bladder samples, respectively.
EXPERIMENTAL VALIDATION OF miRNA MARKERS WITH MICROARRAY
HYBRIDIZATION
Our investigation of gene expression in eight clinical BC sam-
ples and four normal bladder samples using an Illumina human
HT-12v4 bead array was only able to trace 33/102 (32%) indi-
vidual miRNA markers that were previously reported (online
Dataset 2, http://small.mrna.ru/files/). Hybridization signals for
individual BC samples were compared to signals for normal tis-
sues. Genes were considered to be differentially expressed if they
met the following criteria: (1) the p-value < 0.01, and (2) the
average BC and normal bladder signals differ at least 1.5-times.
The cancer-to-normal ratio was calculated for all differential BC
signals according to the formula SBC/SaN, where SBC is the BC dif-
ferential hybridization signal, and SaN is the average hybridization
signal for normal bladder samples.
In this test, only two micro RNAs (miR21 and miR205)
showed differential expression in the BC samples under investiga-
tion, with the remaining 94% showing no differential expression.
MiR205 that appeared to be up-regulated in several BC tis-
sue samples was previously reported as up-regulated (Gottardo
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et al., 2007; Dyrskjot et al., 2009; Tao et al., 2011) and down-
regulated (Catto et al., 2009; Wiklund et al., 2011) in BC.
For the two differentially expressed markers, we calculated the
AUC (area-under-the-curve) scores according to the formula
AUC = (Sp + Sn)/2, where Sp is the specificity, and Sn is
the sensitivity of the marker. Markers are typically considered
valuable when their AUC scores exceed 0.7 (Pencina et al.,
2008). According to the MA test, the AUC values for miR21
and miR205, if considered as the “BC up-regulated” mark-
ers, were 0.33 and 0.11, respectively. Therefore, according to
our MA test, miR205 and miR21 showed a poor diagnostic
value. Overall, we observed a large discordance between the
expected (published) results and the results obtained (Figure 1A).
However, due to chip limitations in this MA assay, we were not
able to investigate 69 additional (miRNAs) (online Dataset 2,
http://small.mrna.ru/files/).
EXPERIMENTAL VALIDATION OF miRNA MARKERS WITH
HIGH-THROUGHPUT miRNA SEQUENCING
In a (DS) assay, we compared the sequenced miRNA fractions
from nine human BC samples and from one pooled sample of
six normal human bladder tissue specimens. Short RNAs (19–25
nucleotides long) were isolated and then subjected to sequenc-
ing. The number of reads varied from 1.1 to 9.6 million reads per
library, with a median value of 5.1 (Supplementary Table S3). The
reads were clustered using Galaxy (http://main.g2.bx.psu.edu/)
and attributed to the known micro RNAs using the miRBase14.0
microRNA sequence database (Griffiths-Jones et al., 2006) and
the PostParser sequence mapping tool (Baskaev et al., 2012). The
number of reads that could be attributed to the known miRNAs
varied between 78 and 93% in different libraries, with a median
value of 87% (online Dataset 3, http://small.mrna.ru/files/).
Of the 102 published BC-associated marker miRNAs, we
found 38 (37%) among the mapped and sequenced miRNAs.
The expression level ratios of miRNAs in the samples under
comparison (BC vs. non-BC) were evaluated by calculating the
RBC/RNratio, where RBCis a normalized number of reads in an
individual miRNA molecule in a BC library, and RNis a normal-
ized number of reads of the same miRNA molecule in a mixed
normal bladder tissue sample (Supplementary Table S4).
The DS data on differential expression was significantly closer
to the published literature than the results received with SSH and
MA methods. For each sample, we calculated the RBC/RNratio
and then obtained the proportion of up- or down-regulated
miRNAs in BC samples. MiRNA was considered to be up-
regulated if the number of samples with the value RBC/RN > 2
was more than the number of samples with the value RBC/RN <
0.5. According to this criterion, 87% (33/38) of the sequenced
marker miRNAs showed an expression status similar to that in
the published data (Figures 1A,B). For stricter criterion values
(a RBC/RNratio greater than 3 or less than 0.33, and greater
than 4 or less than 0.25), the proportion of sequenced miR-
NAs in agreement with the published data was 74% (28/38) and
66% (25/38), respectively. Among the 38 investigated miRNAs
that matched the DS data, 20 were up-regulated and 15 were
down-regulated in BC. Three remaining miRNAs were up- and
down-regulated in equal numbers to the investigated BC tissues.
Six of the 38 sequencedmarkermiRNAs exhibited expression pro-
files that differed from the published data. MiR126, miR146a,
miR34a, andmiR493 were published as down-regulated (Lodygin
et al., 2008; Saito et al., 2009; Veerla et al., 2009; Ueno et al.,
2012), and miR199b and miR26b were published as up-regulated
in BC (Gottardo et al., 2007; Veerla et al., 2009). However,
in our experiments, we observed an opposite expression trend
(Supplementary Table S4).
We calculated sensitivity scores for all of the published
BC miRNA expression markers. Only four miRNAs (miR100,
miR125B, miR143, and Let7c) showed the Sn values >0.7 for the
strict criterion (RBC/RNratio> 3 or< 0.33). Two additional miR-
NAs (miR199A2 and miR205) showed the Sn value >0.7 only
with a soft cut-off criterion RBC/RN > 2 or< 0.5.
Importantly, a large proportion (64/102) of the published
miRNA expression biomarkers was not present in our DS
datasets, which may point to the absence of their expression in
the investigated bladder tissue samples.
COMPARISON OF DATA ON microRNA MARKER EXPRESSION BY SSH,
MH, AND DS ANALYSES
Here, we aimed to evaluate the complete pool of published
miRNA BC markers in a single study using three independent
experimental approaches. We examined 38 of 102 published BC
microRNA markers using a DS analysis of miRNA libraries, 33
miRNAs using an MH analysis, and 42 miRNAs using an SSH
assay. Only our DS analysis data corresponded well with the
published information. The concordance of DS results and the
published data was 87%, whereas for SSH and MH results, it
was 9.5 and 6%, respectively (Figures 1A–C). We were able to
examine 30 published miRNA marker molecules using all three
methods, and we observed only one case when all three methods
agreed: miR205 was up-regulated according to all three datasets
(Figure 1D; online Dataset 4, http://small.mrna.ru/files/). The
congruencies between the experimental datasets are shown on
Figure 1 and Supplementary Tables S5–S7 and online Datasets
5–8 (http://small.mrna.ru/files/).
ANALYSIS OF THE EXPRESSION STATUS OF METHYLATION microRNA
MARKER GENES
Using experimental assays, we analyzed two miRNA markers
differentially methylated in BC according to the published
data: miR744 (hypomethylated) and miR34a (hypermethy-
lated) (Supplementary Table S8). Mir744 participates in post-
transcriptional regulation of TGF-beta1 (Martin et al., 2011)
which directs cellular processes such as proliferation, differen-
tiation, migration, and survival (Blobe et al., 2000). TGF-b1 is
a key regulator of embryogenesis, angiogenesis, wound healing,
and inflammation. Aberrant TGF-b1 expression is implicated in
carcinogenesis (Gordon and Blobe, 2008).
MiR34a directly depends on the activity of TP53 gene prod-
ucts (Chen and Hu, 2012). Inactivating mutations of p53, the
expression of key inhibitors of p53, or genomic mutation at the
p53-binding site within the miR34a gene may cause the loss of
expression of miR34a. MiR34a regulates a plethora of target pro-
teins which induce cell apoptosis; thus, it acts as a key cancer
suppressor (Chen and Hu, 2012).
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According to DS analysis, miR744 was up-regulated in 56% of
the cases, but Mir34a was not differentially expressed in 78% of
the cases and up-regulated in only 22% of the cases.
qRT-PCR VALIDATION OF DATA
In order to clarify what method provides the most adequate
results, we measured expression of seven micro RNAs using
TaqMan probe-based qRT-PCR assay. We chose one micro RNA
(miR183) for which transcription was reported to be upregulated
in BC, four micro RNAs (miR100, 200A, 203, 205), for which
contradictory data were reported, and two micro RNAs (miR143,
199A) published as downregulated in BC. The same tissue sam-
ples as used for DS experiments were used. The results of qRT-
PCR tests showed little congruence with the MH and SSH data,
but were in good agreement with the DS data (Supplementary
Table S9). Micro RNA expression status (up/downregulated or
neutral) coincided for ∼90% of the cases, varying from ∼78
to 100% depending on the individual micro RNA molecule
(Supplementary Table S9). We conclude, therefore, that among
the three methods tested, the DS results fit best with qRT-PCR
data and, thus, can be considered as the most adequate instru-
ment to estimate miRNA content in human bladder tissues.
IMPLICATIONS OF DIFFERENTIALLY EXPRESSED miRNA
Previously, at least two major signaling pathways associated with
BC progression were reported. Abnormal activation of the fibrob-
last growth factor receptor 3 gene (FGFR3) by means of either
overexpression or mutation is cited in approximately 80% of
non-invasive bladder tumors (Billerey et al., 2001). FGFR3 and
many other growth factor receptors participate in the activation
of the RAS-kinase signaling pathway, thus leading to increased
cell proliferation, motility, and cancer transformation through
hyperplasia of normal urothelium (Knowles, 2006).
The second major pathway associated with BC progression
(P53 pathway) is misregulated in muscle-invasive tumors that
mainly contain mutations in the TP53 gene (Neuzillet et al.,
2012). Aberrations of the p53-induced signaling pathway lead to
the development of carcinoma in situ, invasive carcinoma, and
metastases through urothelial dysplasia (Knowles, 2006).
Several studies attempted to identify miRNA molecules tar-
geting key participants of FGFR3 and p53 signaling pathways in
BC (Figure 2). Using bioinformatic methods, the Catto labora-
tory predicted that some miRNA molecules aberrantly expressed
in BC actually targeted the FGFR3 gene product. Examples of this
includemiR145, miR101, miR99a, andmiR100. Furthermore, the
regulation of FGFR3 by miR99a and miR100 was experimentally
validated (Catto et al., 2009). An increase in miR143 expres-
sion in BC cells is accompanied by the lower expression of RAS
genes. Another line of evidence recently confirmed this by show-
ing that induced transcription of miR143 in BC cell lines led to a
decreased expression of RAS (Lin et al., 2009; Kent et al., 2010).
Another study showed that a decrease in miR7 expression is fre-
quently associated with the hyperactive FGFR3 mutation status
found in BC tissues. Key elements of the p53 signaling pathway—
MDM2, MDM4, and ATM gene products—were predicted as
targets for miR10. MiR129 potentially targets MDM4 and ATM
in this pathway; miR125b, miR43, miR30a/c, and miR223 were
predicted to target p53 directly (Fendler et al., 2011). In con-
cordance with these findings, it was reported that expression
levels of miR10, miR125b, and miR222 may serve as predictors
of muscle-invasive carcinomas (Veerla et al., 2009). Using the DS
approach, we assayed 12 of 18 published BC marker miRNAs
that were predicted to target either FGFR3 or TP53 pathways.
Our experimental data matched the published data for seven
miRNAs (miRNAs 29, 30, 100, 101, 125, and 143 were down-
regulated in BC and miR103 was up-regulated) (Figure 2). For
miR100 and miR143, we observed a total suppression of expres-
sion in all studied cases. For miR21 and miR10, we obtained
contradictory data: different patients showed either up- or down-
regulation of their expression. Using DS analysis, we confirmed
the expression of 70% of the published miRNAs which were
predicted to be participants in BC-associated signaling pathways
(Figure 2).
DISCUSSION
MiRNAs can be used as biomarkers for many types of cancers
(Van Roosbroeck et al., 2013). Some miRNAs may help trace
the tissue of origin of cancers whose primary origin is unknown
(Rosenfeld et al., 2008). In addition, miRNAmolecules are advan-
tageous for molecular diagnostics due to their greater stability
in vitro compared to mRNA molecules (Jung et al., 2010).
In this study, we used different methods to profile miRNAs for
the evaluation of the potential utility of published miRNA mark-
ers for BC diagnostics. We used (MH), subtractive suppression
hybridization (SSH), and (DS) technologies to determine miRNA
expression profiles in 17 tissue samples of urothelial bladder
carcinoma and in eight histologically normal urothelial samples.
Among the 95 published miRNA expression markers, only 43
were detected in our samples using the SSH approach followed by
DS; 34markers were detected usingMH analysis; 38 were detected
using the DS assay.
The higher expression level of miR205 in cancer was con-
firmed by all experimental assays. It was previously shown that
ectopic expression of miRNA205 induces apoptosis, cell cycle
arrest, impaired cell viability, cloning, and invasive properties
of cancer cells (Yue et al., 2012). MiR205 can specifically sup-
press VEGF-A expression by directly interacting with the putative
miRNA-205 binding site at the 3′-UTR (Yue et al., 2012). MiR205
also regulates the expression of tumor-suppressor, PTEN. The
introduction of miR205 into CNE-2 cells suppresses PTEN pro-
tein expression followed by the activation of AKT, an increased
number of foci formation, and the reduction of post-irradiation
cell apoptosis (Qu et al., 2012). MiR205 was also reported to
be aberrantly expressed in breast (Adachi et al., 2011), prostate
(Bhatnagar et al., 2010), lung (Tellez et al., 2011), head, and neck
(Kimura et al., 2010), and other cancers.
MA analysis and SSH showed poor correlation between
miRNA expression and the published data, with the largest num-
ber of identified miRNAs characterized as “intact” (not differ-
entially expressed). This may correspond to the methodological
issues inherent in the preparation of cDNA library for both assays.
Oligo-dT primers were used to initiate the synthesis of first-strand
cDNAs for MA and SSH assays. However, most mature miRNAs
may lack poly (A) sequences at their 3′ termini and thus escape
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FIGURE 2 | The dual-pathway model of different types of bladder cancer
development and the miRNAs that regulate these pathways.miRNAs that
were reported to be down-regulated in BC are highlighted in red; up-regulated
miRNAs are highlighted in green. Arrows show up- or down-regulation of
miRNAs under investigation according to DS analysis. Controversial results are
marked by a “?” symbol. Unexplored miRNAs are marked by a “-” symbol.
such types of analysis. Nevertheless, low convergence of MA and
SSH results (without DS analysis) with the qRT-PCR data and
with the published information suggest that they are not infor-
mative for studying miRNA expression profiles. Theoretically,
variations of the MA- and of the SSH-based techniques that do
not rely on the amplification of poly(A)+ sequences may show
somewhat better results for miRNA profiling, but this will be a
matter of further studies.
In contrast, the development of high-throughput DS tech-
nology provides an opportunity for almost complete analyses of
miRNA profiles. DS reveals an abundance of miRNAs and can
identify miRNAs missed by traditional cloning and sequencing
methods (Hurd and Nelson, 2009). At present, DS is considered
to be the gold standard for high-throughput analysis of miRNAs
(Han et al., 2011). Our qRT-PCR experiments confirmed that
among the tested techniques, DS should be used as the method
of choice for assessing miRNA expression in human bladder.
To our knowledge, this is the first systematic study evaluat-
ing the diagnostic potential of published miRNA biomarkers for
BC by large-scale profiling of miRNA expression in pathological
human tissue samples. Our findings suggest that DS analysis is
most likely the best approach for the identification and evalua-
tion of the diagnostic and/or prognostic value of miRNA cancer
biomarkers.
Despite the obvious significance of miRNAs for tumor pro-
gression, the relatively sparse data on miRNAs associated with
bladder oncology suggests that this area necessitates future
research.
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